Earnings summaries and quarterly performance for Inspire Medical Systems.
Executive leadership at Inspire Medical Systems.
Timothy P. Herbert
Detailed
Chief Executive Officer, President, and Chair
CEO
BK
Bryan K. Phillips
Detailed
SVP, General Counsel, Chief Compliance Officer and Corporate Secretary
CW
Carlton W. Weatherby
Detailed
Chief Strategy and Growth Officer
JP
Jason P. Kelly
Detailed
Chief Manufacturing and Quality Officer
JC
John C. Rondoni
Detailed
Chief Product & Innovation Officer
MJ
Melissa J. Mann
Detailed
Chief People Officer
RA
Randall A. Ban
Detailed
Executive Vice President, Patient Access and Therapy Development
RJ
Richard J. Buchholz
Detailed
Chief Financial Officer
Board of directors at Inspire Medical Systems.
CM
Casey M. Tansey
Detailed
Director
CB
Cynthia B. Burks
Detailed
Director
DG
Dana G. Mead, Jr.
Detailed
Director
GL
Gary L. Ellis
Detailed
Lead Independent Director
GG
Georgia Garinois-Melenikiotou
Detailed
Director
MJ
Myriam J. Curet, M.D.
Detailed
Director
ST
Shawn T McCormick
Detailed
Director
SG
Shelley G. Broader
Detailed
Director
Research analysts who have asked questions during Inspire Medical Systems earnings calls.
Adam Maeder
Piper Sandler Companies
4 questions for INSP
Also covers: ABT, AXNX, EW +13 more
AP
Anthony Petrone
Mizuho Group
4 questions for INSP
Also covers: ADMA, ALC, BSX +22 more
Brett Fishbin
KeyBanc Capital Markets
4 questions for INSP
Also covers: ALC, COO, ICUI +6 more
DA
Danielle Antalffy
UBS Group AG
4 questions for INSP
Also covers: ABT, ATRC, BAX +15 more
DR
David Rescott
Baird
4 questions for INSP
Also covers: HAE, IRTC, LIVN +7 more
Jonathan Block
Stifel Financial Corp.
4 questions for INSP
Also covers: ALGN, COO, CUTR +11 more
RN
Richard Newitter
Truist Securities
4 questions for INSP
Also covers: AXNX, DXCM, GKOS +18 more
RM
Robert Marcus
JPMorgan Chase & Co.
4 questions for INSP
Also covers: ABT, BAX, BDX +21 more
SS
Shagun Singh Chadha
RBC Capital Markets
4 questions for INSP
Also covers: AXNX, DXCM, GMED +11 more
Travis Steed
Bank of America
4 questions for INSP
Also covers: ABT, AXNX, BAX +19 more
Christopher Pasquale
Nephron Research
3 questions for INSP
Also covers: ALC, AXGN, BSX +12 more
LB
Larry Biegelsen
Wells Fargo & Company
3 questions for INSP
Also covers: ABT, ALC, AXNX +24 more
Michael Polark
Wolfe Research
3 questions for INSP
Also covers: BSX, DXCM, EMBC +11 more
MS
Michael Sarcone
Jefferies
3 questions for INSP
Also covers: ALC, AXGN, CTSO +11 more
Michael Kratky
Leerink Partners
2 questions for INSP
Also covers: AXGN, BBNX, DXCM +6 more
SK
Suraj Kalia
Oppenheimer & Co. Inc.
2 questions for INSP
Also covers: ABT, AORT, ATRC +14 more
BN
Brett Netson
Leerink Partners
1 question for INSP
Chris Pasquale
Nephron Research LLC
1 question for INSP
Also covers: ALC, AXGN, BSX +7 more
Kallum Titchmarsh
Morgan Stanley
1 question for INSP
Also covers: ATEC, AXNX, EMBC +5 more
LB
Lawrence Biegelsen
Wells Fargo
1 question for INSP
Also covers: ABT, ALC, BAX +16 more
Mike Kratky
Leerink Partners
1 question for INSP
Also covers: AXGN, DXCM, MDT +4 more
Mike Polark
Wolfe Research, LLC
1 question for INSP
Also covers: BBNX, BSX, DXCM +6 more
Recent press releases and 8-K filings for INSP.
Inspire Medical Systems Faces Securities Class Action Lawsuit
INSP
Legal Proceedings
Guidance Update
Product Launch
- Bernstein Litowitz Berger & Grossmann LLP (BLB&G) filed a securities class action lawsuit against Inspire Medical Systems, Inc. and certain senior executives, covering investors who purchased common stock between August 6, 2024, and August 4, 2025.
- The lawsuit alleges misrepresentations concerning the launch of the Inspire V device, specifically regarding issues with demand, reimbursement codes, and the readiness of treatment centers for training and IT integration.
- The alleged truth became apparent on August 4, 2025, when Inspire announced an 80% reduction in its full-year earnings per share guidance, leading to a 32.4% decline in its common stock price, or $42.04 per share.
2 days ago
Inspire Medical Systems Faces Securities Fraud Lawsuit
INSP
Legal Proceedings
Demand Weakening
Profit Warning
- A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (INSP), alleging the company misled investors by concealing critical operational failures during the launch of its next-generation Inspire V device.
- The lawsuit claims that undisclosed issues, including Medicare claims software failures and an excess inventory of the older Inspire IV device, led to a catastrophic guidance cut and a $42.04 per share stock drop, representing a 32.4% decline in value.
- Investors who purchased INSP securities between August 6, 2024, and August 4, 2025, are part of the Class Period, with a Lead Plaintiff Deadline of January 5, 2026.
2 days ago
Inspire Medical Systems Faces Shareholder Investigation and Class Action Lawsuit
INSP
Legal Proceedings
Product Launch
Guidance Update
- Faruqi & Faruqi, LLP is investigating potential securities law violations at Inspire Medical Systems (NYSE: INSP) and has filed a federal securities class action on behalf of investors who purchased securities between August 6, 2024, and August 4, 2025.
- The lawsuit alleges that the company made false or misleading statements and/or failed to disclose key facts regarding its Inspire V device, including actual market demand and necessary launch steps.
- On August 4, 2025, Inspire Medical Systems announced significant setbacks for the Inspire V launch, citing slow rollout due to incomplete training, contracting, and onboarding at treatment centers, as well as billing and reimbursement challenges.
- These issues, combined with weak demand and excess inventory, led the company to cut its 2025 earnings guidance by more than 80%.
- Following these revelations, Inspire's stock price fell over 32% on August 4-5, 2025, wiping out approximately $1.2 billion in market capitalization.
3 days ago
Inspire Medical Systems Faces Securities Class Action Lawsuit
INSP
Legal Proceedings
Product Launch
Guidance Update
- A federal securities class action lawsuit has been filed against Inspire Medical Systems (INSP) alleging false or misleading statements regarding the Inspire V device's market demand and launch readiness. The deadline for investors to seek the role of lead plaintiff is January 5, 2026.
- On August 4, 2025, the company disclosed significant setbacks for the Inspire V launch, citing delayed rollout due to incomplete training and onboarding at treatment centers, as well as billing and reimbursement challenges.
- These issues, coupled with weak demand and excess inventory for Inspire V, forced Inspire Medical to sharply cut its 2025 earnings guidance by more than 80%. The stock price subsequently fell more than 32% in a single day, resulting in a loss of approximately $1.2 billion in market capitalization.
4 days ago
Inspire Medical Systems Faces Securities Class Action Lawsuit Over Inspire V Launch Failures
INSP
Legal Proceedings
Guidance Update
Product Launch
- A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (INSP), alleging the company concealed critical failures in billing software and training that hindered the successful launch of its Inspire V device.
- The alleged operational failures resulted in an 80% cut to EPS guidance and caused the stock to crash over 32%.
- The lawsuit covers investors who purchased INSP securities between August 6, 2024, and August 4, 2025, with the deadline to move for lead plaintiff appointment set for January 5, 2026.
7 days ago
Inspire Medical Systems Faces Securities Class Action Lawsuit Over Inspire V Launch Setbacks
INSP
Legal Proceedings
Product Launch
Guidance Update
- Faruqi & Faruqi, LLP is investigating Inspire Medical Systems (INSP) for potential federal securities law violations, alleging the company made misleading statements and failed to disclose key facts about its Inspire V device launch.
- On August 4, 2025, Inspire Medical announced significant setbacks for Inspire V, including a slow rollout due to incomplete training and onboarding at treatment centers, billing and reimbursement challenges, weak demand, and excess inventory.
- These issues resulted in a cut of over 80% to its 2025 earnings guidance and caused Inspire's stock price to fall more than 32% on August 5, 2025, wiping out approximately $1.2 billion in market capitalization.
- Investors who purchased securities between August 6, 2024, and August 4, 2025, have until January 5, 2026, to seek lead plaintiff status in the class action lawsuit.
7 days ago
Inspire Medical Systems Faces Class Action Lawsuit
INSP
Legal Proceedings
Demand Weakening
Guidance Update
- A class action lawsuit has been initiated against Inspire Medical Systems, Inc. (NYSE:INSP), with a Lead Plaintiff Deadline of January 5, 2026.
- The lawsuit alleges that during the Class Period of August 6, 2024, through August 4, 2025, the company made false and/or misleading statements regarding the Inspire V launch, which allegedly suffered from poor demand, surplus inventory, and incomplete essential tasks.
- These issues led Inspire Medical to reduce its 2025 earnings guidance by more than 80%, resulting in a more than 32% decline in its common stock price.
Dec 13, 2025, 2:16 PM
Inspire Medical Systems Faces Securities Fraud Lawsuit Over Inspire V Launch Failures
INSP
Legal Proceedings
Product Launch
Guidance Update
- A securities class action lawsuit has been filed against Inspire Medical Systems (INSP), alleging the company misled investors by concealing critical operational failures during the launch of its Inspire V device for obstructive sleep apnea.
- The lawsuit claims that undisclosed issues, including Medicare claims software not being ready until July 1, 2025, an excess inventory of the older Inspire IV device, and insufficient training for the new device, led to a catastrophic guidance cut.
- These alleged failures resulted in Inspire Medical Systems' stock experiencing a $42.04 per share drop and a 32.4% decline in value.
- Investors who purchased INSP securities between August 6, 2024, and August 4, 2025, are part of the class period, with a Lead Plaintiff Deadline of January 5, 2026.
Dec 11, 2025, 8:20 PM
Inspire Medical Systems Faces Securities Class Action Investigation Over Inspire V Launch Setbacks
INSP
Legal Proceedings
Product Launch
Guidance Update
- Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. for alleged federal securities law violations, with a January 5, 2026 deadline for investors to seek the role of lead plaintiff in a federal securities class action.
- The investigation stems from allegations that Inspire Medical made false or misleading statements and failed to disclose key facts about its Inspire V device, including actual market demand and the necessary steps for a successful launch.
- On August 4, 2025, the company announced significant setbacks for the Inspire V launch, attributing delays to incomplete training, contracting, and onboarding at treatment centers, as well as billing and reimbursement challenges, weak demand, and excess inventory.
- These issues forced Inspire Medical to sharply cut its 2025 earnings guidance by more than 80%.
- Following these revelations, Inspire's stock price fell more than 32% in a single day, from $129.95 to $87.91, wiping out approximately $1.2 billion in market capitalization.
Dec 11, 2025, 3:31 PM
Inspire Medical Systems Faces Securities Class Action Lawsuit Over Inspire V Launch Failures
INSP
Legal Proceedings
Guidance Update
Product Launch
- Hagens Berman has filed a securities class action lawsuit against Inspire Medical Systems (INSP), alleging the company misled investors about the "operational readiness" for its Inspire V device launch.
- The lawsuit claims Inspire concealed critical failures in billing software and training, including that Medicare claims processing software updates did not take effect until July 1, 2025, and an undisclosed inventory glut of the older Inspire IV device.
- These alleged issues resulted in an 80% cut to 2025 EPS guidance and caused INSP's stock to crash over 32%, or $42.04 per share, on August 4, 2025.
- The lawsuit covers investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, with the deadline to move for lead plaintiff appointment set for January 5, 2026.
Dec 9, 2025, 5:58 PM
Quarterly earnings call transcripts for Inspire Medical Systems.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more